Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 for Radioiodine Refractory Thyroid Cancer
NCT00936858Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2009
- Primary completion
- Feb 2020
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in thyroid cancer, sponsored by Dana-Farber Cancer Institute. Started Jul 2009; status: completed.
02
Drugs
everolimus
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT00936858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936858.